Dr. Jose M. Pacheco
Claim this profileUniversity of Colorado Hospital
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
17 reported clinical trials
30 drugs studied
About Jose M. Pacheco
Education:
- Earned an MD from the University of Texas Medical Branch in 2010.
Experience:
- Possesses over 13 years of experience in the medical field.
- Specializes in Hematology & Oncology.
- Board certified in Internal Medicine and Medical Oncology.
- Affiliated with Avista Adventist Hospital, Littleton Adventist Hospital, UCHealth Highlands Ranch Hospital, and UCHealth University of Colorado Hospital.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Jose M. Pacheco is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Amivantamab + TKI
for Lung Cancer
Although non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK), c-ros oncogene 1(ROS1), and ret proto-oncogene (RET) gene fusions initially respond well to tyrosine kinase inhibitor (TKI) therapies, acquired resistance is inevitable. In many of these cases, increased activation of the erythroblastic leukemia viral oncogene homologue (ERBB) or cMet pathways appears to be a bypass signaling mechanism that allows these cancer cells to circumvent the selective pressure from TKIs. Recent data have suggested that these pathways compensate for each other in situations where one pathway is inhibited, leading to "kinase switch" drug resistance. Thus, the expected inhibition of both pathways via treatment with the amivantamab and combination TKI combination may improve overall efficacy by limiting the compensatory pathway activation.
Recruiting1 award Phase 1 & 215 criteria
More about Jose M. Pacheco
Clinical Trial Related5 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Jose M. Pacheco has experience with
- Pembrolizumab
- Atezolizumab
- Carboplatin
- Talazoparib
- Pemetrexed Disodium
- Gemcitabine Hydrochloride
Breakdown of trials Jose M. Pacheco has run
Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jose M. Pacheco specialize in?
Jose M. Pacheco focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jose M. Pacheco currently recruiting for clinical trials?
Yes, Jose M. Pacheco is currently recruiting for 5 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Jose M. Pacheco has studied deeply?
Yes, Jose M. Pacheco has studied treatments such as Pembrolizumab, Atezolizumab, Carboplatin.
What is the best way to schedule an appointment with Jose M. Pacheco?
Apply for one of the trials that Jose M. Pacheco is conducting.
What is the office address of Jose M. Pacheco?
The office of Jose M. Pacheco is located at: University of Colorado Hospital, Aurora, Colorado 80045 United States. This is the address for their practice at the University of Colorado Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.